Top News

KAI Pharmaceuticals Acquired By Amgen For $315M

South San Francisco-based KAI Pharmaceuticals, a biopharmaceuticals firm development treatment of secondary hyperparathroidism in patients with chronic kidney disease on dialysis, has been acquired by Amgen, the firms said today. Amgen said it would pay $315M in cash for KAI Pharmaceuticals, which was venture backed by InterWest Partners, Skyline Ventures, Intersouth Partners, Aberdare Ventures, Investor Growth Capital, Kearny Venture Partners, Lumira Capital and Delphi Ventures.


 

Marketplace


blog comments powered by Disqus
 

Latest Headlines

Browse Issues